Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Cash & Equivalents: 2014-2025

Historic Cash & Equivalents for AC Immune (ACIU) over the last 12 years, with Sep 2025 value amounting to $34.7 million.

  • AC Immune's Cash & Equivalents fell 7.32% to $34.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $34.7 million, marking a year-over-year decrease of 7.32%. This contributed to the annual value of $34.7 million for FY2025, which is N/A change from last year.
  • AC Immune's Cash & Equivalents amounted to $34.7 million in FY2025, which was up 83,646.43% from $41,409 recorded in FY2024.
  • In the past 5 years, AC Immune's Cash & Equivalents ranged from a high of $90.0 million in FY2021 and a low of $41,409 during FY2024.
  • Over the past 3 years, AC Immune's median Cash & Equivalents value was $88,491 (recorded in 2023), while the average stood at $11.6 million.
  • Data for AC Immune's Cash & Equivalents shows a maximum YoY plummeted of 99.73% (in 2023) over the last 5 years.
  • Over the past 5 years, AC Immune's Cash & Equivalents (Yearly) stood at $90.0 million in 2021, then plummeted by 63.56% to $32.8 million in 2022, then plummeted by 99.73% to $88,491 in 2023, then crashed by 53.21% to $41,409 in 2024, then reached $34.7 million in 2025.